ABLI.ST

Abliva AB (publ) [ABLI.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ABLI.ST Stock Summary

In the News

ABLI.ST Financial details

Company Rating
-
Market Cap
170.28M
Income
-95.52M
Revenue
137K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
23 Feb 2024
P/E
-3.12
Forward P/E
-
PEG
1.75
P/S
-
P/B
2.86
P/C
-
P/FCF
-17.88
Quick Ratio
4.61
Current Ratio
6.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.09
EPS next Y
-
EPS next Q
-
EPS this Y
-17.82%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-27.13%
Revenue last 5Y
0.44%
Revenue Q/Q
-
EPS Q/Q
-23.4%
-
-
-
-
SMA20
-2.22%
SMA50
4.76%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-81%
ROE
-65%
ROC
-0.92%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.14-0.316
52W High
-
52W Low
-
RSI
54.74
Rel Volume
0.4
Avg Volume
1.42M
Volume
565.71K
Perf Week
0.45%
Perf Month
2.42%
Perf Quarter
-
Perf Half Y
169.74%
-
-
-
-
Beta
1.056
-
-
Volatility
0%, 0.01%
Prev Close
0.23%
Price
0.444
Change
0.23%

Something similar

Top by Market Cap
MSF.DE
APC.DE
1YD.DE
VTSAX
M&M.NS
Same Sector
LOWLF
CVET
000623.SZ
POLYMED.NS
CRW.L
Check Those
WAGTX
MIGO.L
600332.SS
ARTO.JK
002447.SZ
Similar Market Cap
2363.HK
EDAP
SAGA.L
DDWM
8167.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 1.42M
  • Market Capitalization 170.28M
  • Employee 8
  • CEO Dr. Ellen K. Donnelly Ph.D.
  • Headquarters Lund,SE
  • IPO Date 2008-10-03
  • Website https://abliva.com

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.